Research for endocrinological disorders associated with immune checkpoint inhibitors

Conditions

Cancer patients treated with immune checkpoint inhibitors

Tomoko Kobayashi, Shintaro Iwama, Daisuke Sugiyama, Yoshinori Yasuda, Takayuki Okuji et al. (16 authors)

Journal for ImmunoTherapy of Cancer2021-05-0175 citations

10.1136/jitc-2021-002493

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study

Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, Norio Okada, Takayuki Okuji et al. (27 authors)

Journal for ImmunoTherapy of Cancer2020-06-30119 citations

10.1136/jitc-2020-000779

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study.

Okada N, Iwama S, Okuji T, Kobayashi T, Yasuda Y, Wada E, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Hase T, Morise M, Kanda M, Yokota K, Hashimoto N, Ando M, Fujimoto Y, Nagino M, Kodera Y, Fujishiro M, Hibi H, Sone M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H.

2020-02-0359 citations

10.1038/s41416-020-0736-7

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients treated with immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: Cancer patients not treated with immune checkpoint inhibitors

Design outcomes

Primary

Measure	Time frame
Development of endocrine adverse events after treatment with immune checkpoint inhibitors	—

Secondary

Measure	Time frame
Changes in pituitary, thyroid, and diabetes hormones as well as the presence of anti-pituitary antibodies Findings of pituitary MRI	—

Countries

Japan

Contacts

Public ContactShintaro Iwama

Nagoya University Hospital Department of Endocrinology and Diabetes

siwama@med.nagoya-u.ac.jp+81-52-744-2142

Outcome results